Edwards Lifesciences Corp (EW)vsTriSalus Life Sciences Inc. (TLSI)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
TLSI
TriSalus Life Sciences Inc.
$4.01
+3.08%
HEALTHCARE · Cap: $238.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 13338% more annual revenue ($6.07B vs $45.15M). EW leads profitability with a 17.7% profit margin vs -86.9%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
TLSI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Revenue surging 59.8% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -5.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : TLSI
The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : TLSI
The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while TLSI is a hypergrowth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
TLSI is growing revenue faster at 59.8% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 25/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is a cutting-edge biopharmaceutical firm committed to transforming cancer therapies through its proprietary localized drug delivery technologies. By enhancing the efficacy of immuno-oncology agents and overcoming significant distribution barriers within the tumor microenvironment, TriSalus aims to significantly improve patient outcomes in oncology. The company is advancing a robust pipeline of clinical programs that reflect its innovative approach and dedication to addressing the unmet needs of patients with challenging cancers. With a focus on expanding access to effective therapies, TriSalus is well-positioned to make a meaningful impact in the field of cancer treatment.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?